预约演示
更新于：2025-10-20
Nemonoxacin Malate
苹果酸奈诺沙星
更新于：2025-10-20
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 中国 (2016-05-27), |
最高研发阶段(中国)批准上市 |
特殊审评特殊审批 (中国) |
登录后查看时间轴
结构/序列
分子式C24H31N3O9 |
InChIKeyYMVJINCWEIPOFL-FXMYHANSSA-N |
CAS号951163-60-3 |
关联
17
项与 苹果酸奈诺沙星 相关的临床试验CTR20231866
评价苹果酸奈诺沙星胶囊治疗单纯性尿路感染的有效性与安全性的多中心、随机、双盲、左氧氟沙星平行对照的Ⅲ期临床研究
CTR20181341
评价口服苹果酸奈诺沙星（Nemonoxacin）治疗成人社区获得性肺炎患者的有效性和安全性的多中心Ⅳ期临床研究
NCT05133752
A Multi-Center, Open-Label, Single-Arm, Phase IV Study to Evaluate the Safety and Clinical Efficacy of Oral Administration With Nemonoxacin in Treating Elderly Patients With Community-Acquired Pneumonia
100 项与 苹果酸奈诺沙星 相关的临床结果
登录后查看更多信息
100 项与 苹果酸奈诺沙星 相关的转化医学
登录后查看更多信息
100 项与 苹果酸奈诺沙星 相关的专利（医药）
登录后查看更多信息
85
项与 苹果酸奈诺沙星 相关的文献（医药）2025-10-03JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
Phenotypic and genotypic profiles of clinical isolates of various Nocardia species to carbapenems and fluoroquinolones
Article
作者: Xue, Jiaoyu ; Jiang, Tingfei ; Zhang, Mingrui ; Shi, Dongyan ; Yang, Jing
Abstract:
Objectives:
To establish patterns of the antimicrobial susceptibility of Nocardia species to carbapenems and fluoroquinolones and analysis of phenotypic–genotypic correlations.
Methods:
Isolates were identified to the species using 16S rRNA, secA1, or rpoB gene sequencing analysis. The antimicrobial susceptibility testing was performed using the broth microdilution method, and WGS was employed to analyse the presence of resistance genes and/or mutations of Nocardia species against carbapenems and fluoroquinolones.
Results:
Among 143 Nocardia isolates, N. farcinica (27.27%, 39/143) and N. cyriacigeorgica (25.17%, 36/143) were the most common species, followed by N. abscessus Complex (18.88%, 27/143). The MIC90s of the seven carbapenems were 8 mg/L for doripenem, 8 mg/L for meropenem, 16 mg/L for ertapenem, 16 mg/L for biapenem, 64 mg/L for imipenem, 64 mg/L for faropenem and 128 mg/L for tebipenem, respectively. The susceptibility rates to imipenem were 76.9% and 88.9% for N. farcinica and N. cyriacigeorgica, respectively, but only 14.3% and 0% for N. otitidiscavarium and N. brasiliensis, respectively. Further, 90% of N. brasiliensis and 50% of N. otitidiscaviarum isolates were susceptible and intermediate to meropenem. WGS identified blaFAR-1 gene in N. farcinica and blaAST-1 gene in N. cyriacigeorgica, respectively. The MIC90s of the four fluoroquinolones were 1 mg/L for sitafloxacin, 4 mg/L for nemonoxacin, 4 mg/L for moxifloxacin and 16 mg/L for ciprofloxacin, respectively. The susceptibility rate of Nocardia species to ciprofloxacin was low except for N. farcinica. The resistance to fluoroquinolones arise from mutations in the gyrA gene.
Conclusions:
Nocardia spp. exhibited varying patterns of susceptibility to carbapenems and fluoroquinolones respectively. Importantly, different Nocardia spp. exhibited different patterns of susceptibility to carbapenems and fluoroquinolones, respectively.
2025-09-23Cureus Journal of Medical Science
Safety and Efficacy of Nemonoxacin vs Levofloxacin in Patients With Community-Acquired Pneumonia: A Systematic Review and Meta-Analysis of Randomized Control Trials
作者: Khan, Alina S ; Muhammad, Alina A ; Ahmed, Komal F ; Varrassi, Giustino ; Khatri, Mahima ; Lodhi, Muniba F ; Mazhar, Fariha ; Kumar, Satesh ; Iqbal, Arham
[This corrects the article DOI: 10.7759/cureus.37650.].
2025-07-01AMERICAN FAMILY PHYSICIAN
Top 20 Research Studies of 2024 for Primary Care Physicians.
Review
作者: Ebell, Mark H ; Grad, Roland
This article summarizes the top 20 research studies of 2024 identified as POEMs (patient-oriented evidence that matters). Based on a network meta-analysis, the oral antibiotics most likely to be effective for community-acquired pneumonia are telithromycin (not available in the United States), azithromycin, amoxicillin-clavulanate, and the quinolones levofloxacin and nemonoxacin (not available in the United States). The oral antivirals molnupiravir and nirmatrelvir-ritonavir reduce hospitalizations in immunocompromised patients with COVID-19. In average-risk infants, a single dose of nirsevimab reduces hospitalizations due to respiratory syncytial virus. Amoxicillin with or without clavulanate is more effective than placebo for children with symptoms of acute sinusitis. Benzyl benzoate 25% is highly effective for scabies in adolescents and adults. Lactobacillus-containing probiotics reduce the incidence of recurrent urinary tract infections (UTIs) in premenopausal women with frequent UTIs. Low-dose amitriptyline is effective as second-line therapy for irritable bowel syndrome. For patients with uncomplicated gallstones, conservative management is a reasonable option. Sodium-glucose cotransporter-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists are better than older drugs at improving patient-oriented outcomes for type 2 diabetes. Continuous or intermittent glucose monitoring is minimally effective for control of type 2 diabetes and can be harmful. Phentermine-topiramate and GLP-1 receptor agonists are the most effective drugs for promoting weight loss. Semaglutide is effective for secondary prevention of cardiovascular disease in people with obesity and no diabetes. SGLT-2 inhibitors and GLP-1 receptor agonists decrease cardiovascular death in older adults with type 2 diabetes and heart failure. Beta blockers do not prevent subsequent events after myocardial infarction in patients with preserved ejection fraction. For patients who do not quit smoking after a trial of varenicline or combined nicotine replacement therapy, a higher dose of either drug can increase quit rates. e-Cigarettes increase abstinence from smoking, but long-term vaping is a consequence for some. Oral naltrexone and acamprosate are safe and effective treatments for alcohol use disorder. Cognitive behavior therapy can reduce fatigue attributed to long COVID. New monoclonal antibodies for Alzheimer disease are harmful, expensive, and minimally effective. Clinicians may choose to deliver bad news in person or by telephone, using their judgment or patient preference to decide which is best for the patient.
100 项与 苹果酸奈诺沙星 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 社区获得性肺炎 | 中国 | 2016-05-27 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 感染 | 申请上市 | 俄罗斯 | 2022-01-30 | |
| 泌尿道感染 | 临床3期 | 中国 | 2023-08-29 | |
| 细菌性肺炎 | 临床3期 | 俄罗斯 | 2016-05-04 | |
| 糖尿病足感染 | 临床2期 | 美国 | 2008-06-01 | |
| 糖尿病足感染 | 临床2期 | 南非 | 2008-06-01 | |
| 糖尿病足感染 | 临床2期 | 中国台湾 | 2008-06-01 | |
| 糖尿病足感染 | 临床2期 | 泰国 | 2008-06-01 | |
| 功能障碍 | 临床1期 | 中国 | 2017-04-05 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 342 | Placebo (100 ml)+Nemonoxacin (Nemonoxacin) | 醖衊製簾鑰獵繭製顧衊: Difference in percentage = 6.1 (95% CI, -0.7 ~ 13.0); Odds Ratio (OR) = 1.45 (95% CI, 0.49 ~ 4.29), P-Value = 0.499 更多 | - | 2023-02-16 | ||
Placebo (250 ml)+Tavanic (Tavanic®) | |||||||
临床1期 | 10 | (Moderate Hepatic Impairment Group) | 選範壓積齋襯鑰積繭夢(簾淵鹹鹽壓夢簾鏇積糧) = 鑰構淵衊構構顧憲鬱壓 壓夢鹹繭鬱顧繭壓鹽膚 (艱網製糧艱顧簾糧襯選, (17.30)) | - | 2019-03-01 | ||
(Healthy Control Group) | 選範壓積齋襯鑰積繭夢(簾淵鹹鹽壓夢簾鏇積糧) = 製夢膚膚齋憲選鹽鑰積 壓夢鹹繭鬱顧繭壓鹽膚 (艱網製糧艱顧簾糧襯選, (10.16)) | ||||||
临床3期 | 527 | 齋憲憲壓構鬱憲廠齋壓(鏇淵糧艱繭顧網壓夢廠) = The incidence of adverse events (AEs) was comparable between nemonoxacin (33.1%, 118/356) and levofloxacin (33.3%, 57/171) 願壓積鏇鬱衊衊鑰蓋鑰 (鏇製築網糧獵積網範獵 ) | 积极 | 2019-02-01 | |||
临床2期 | 192 | 襯築鏇築構遞簾獵顧繭(獵齋膚鏇觸顧窪糧衊繭) = Most drug-related adverse events were mild and transient, mainly gastrointestinal symptoms such as nausea and vomiting, transient neutropenia, and elevated liver enzymes 鹹鑰願餘鏇鹽構鹹壓蓋 (壓齋憲艱淵遞廠選夢壓 ) 更多 | 积极 | 2017-12-01 | |||
临床2期 | - | 207 | 鹹廠窪簾範觸糧夢網襯(顧構獵醖廠醖淵觸窪憲) = 艱衊獵構糧齋簾糧壓積 蓋膚蓋鑰顧鏇鏇糧蓋壓 (齋顧餘顧齋齋醖鬱鬱衊 ) 更多 | - | 2015-03-01 | ||
鹹廠窪簾範觸糧夢網襯(顧構獵醖廠醖淵觸窪憲) = 簾鹽壓憲淵蓋窪膚製積 蓋膚蓋鑰顧鏇鏇糧蓋壓 (齋顧餘顧齋齋醖鬱鬱衊 ) 更多 | |||||||
临床2期 | 207 | (Nemonoxacin 500 mg) | 獵衊鏇壓構糧鹹積膚壓 = 醖鹹衊鬱壓鹽繭齋齋窪 繭製遞築鬱膚製遞蓋蓋 (鬱膚衊簾壓鹽築觸鏇糧, 壓築鬱鑰餘願鏇蓋顧鹹 ~ 積觸憲憲獵齋膚襯艱鬱) 更多 | - | 2015-02-18 | ||
(Nemonoxacin 650 mg) | 獵衊鏇壓構糧鹹積膚壓 = 遞餘壓鹹遞糧糧艱齋顧 繭製遞築鬱膚製遞蓋蓋 (鬱膚衊簾壓鹽築觸鏇糧, 遞窪襯構鏇壓遞製鏇獵 ~ 鹹鏇願壓鏇醖蓋衊範繭) 更多 | ||||||
临床2期 | - | 92 | 壓壓簾選淵鹹鹹觸襯壓(鏇鹹構顧醖鑰餘獵鹹範) = 鏇鏇憲衊廠觸鹹顧夢顧 廠餘餘鹹構夢簾範艱壓 (壓鑰餘壓築廠鹽襯範築 ) 更多 | - | 2014-10-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用